Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2929–2952 of 10,825 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Developmental Defect Clear all

Conditions: Spinocerebellar Ataxia
Interventions: IVIG; Biological
Lead sponsor: University of South Florida; Other
Eligibility: 10 Years to 50 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Turner Syndrome, Short Stature
Interventions: Vosoritide; Drug
Lead sponsor: Roopa Kanakatti Shankar, MBBS, MS; Other
Eligibility: 3 Years to 11 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hemophilia A
Interventions: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, PEGylated Recombinant Factor VIII; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Up to 11 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: Phoenix, Arizona • Denver, Colorado • Gainesville, Florida + 9 more

Conditions: LGMD2I
Interventions: BBP-418; Drug
Lead sponsor: ML Bio Solutions, Inc.; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Parkinson Disease, Huntington Disease
Interventions: Group Drumming Music Therapy; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Down Syndrome
Interventions: Exercise; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Single-ventricle, Fontan Circulation
Interventions: Lower extremity compression garments, Without compression garments; Device · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Patent Foramen Ovale, Cryptogenic Stroke, Embolic Infarction
Interventions: intravenous access in greater saphenous vein compared to upper extremity site.; Diagnostic Test
Lead sponsor: St. John's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Maple Grove, Minnesota

Conditions: Sickle Cell Disease
Interventions: Voxelotor; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 18
States / cities: Birmingham, Alabama • Mobile, Alabama • Atlanta, Georgia + 15 more

Conditions: Cancer
Interventions: methotrexate, methylprednisolone, prednisone; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Gaucher Disease Type 1
Interventions: FLT201; Genetic
Lead sponsor: Spur Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more

Conditions: Prader-Willi Syndrome
Interventions: Nutropin AQ; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 16 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions: decitabine, natural killer cell therapy, aldesleukin, laboratory biomarker analysis; Drug · Biological · Other
Lead sponsor: Sumithira Vasu; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cardiomyopathy, Dilated
Interventions: Mysorba; Device
Lead sponsor: Asahi Kasei Medical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Rochester, Minnesota • Cleveland, Ohio

Conditions: Healthy, Infant, Newborn, Diseases
Interventions: Not listed
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 1 Day to 4 Months
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Cystic Fibrosis
Interventions: Ivacaftor, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 34
States / cities: Birmingham, Alabama • Anchorage, Alaska • Oakland, California + 30 more

Conditions: HIV Infections, Lipodystrophy
Interventions: Pravastatin sodium, Fenofibrate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 57
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 33 more

Conditions: Sickle Cell Disease
Interventions: IMR-687, Placebo; Drug
Lead sponsor: Cardurion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 7
States / cities: Oakland, California • Farmington, Connecticut • Hollywood, Florida + 3 more

Conditions: Arnold-Chiari Malformation, Type 1, Chiari Malformation Type I, Type I Arnold-Chiari Malformation, Syringomyelia
Interventions: Posterior fossa decompression, Dural Augmentation; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Up to 21 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Duchenne Muscular Dystrophy Cardiomyopathy, Cardiomyopathy, Dilated
Interventions: Ifetroban, Placebo; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 7 Years and older · Male only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 10
States / cities: Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 7 more

Conditions: Becker Muscular Dystrophy
Interventions: Tadalafil, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Hemophilic Arthropathy
Interventions: TRM-201 (Rofecoxib), Placebo; Drug
Lead sponsor: Tremeau Pharmceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 19
States / cities: Los Angeles, California • Orange, California • Sacramento, California + 15 more

Conditions: Neurofibromatosis Type 1, Reading Disabilities
Interventions: Tutoring Program I, Tutoring Program II; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 184 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Roche Global Development; Other
Eligibility: 13 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 23
States / cities: Beverly Hills, California • Irvine, California • Los Angeles, California + 16 more

Search by objective public record fields.

Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia

Vosoritide for Short Stature in Turner Syndrome

BAX 855 Pediatric Study

Study of BBP-418 in Patients With LGMD2I

Group Drum-Based Music Therapy Intervention for Parkinson's Disease/Huntington's Disease

Blood Flow and Blood Pressure Investigation in Down Syndrome

Venous Compression in Fontan

Comparison of Lower vs Upper Extremity Injection Agitated Saline to Identify Patent Foramen Ovale With Echocardiography

Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant

A Gaucher Disease Gene Therapy Trial With FLT201

Growth Hormone Use in Adults With Prader-Willi Syndrome

Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Immunoadsorption Therapy for Patients With Non-Ischemic Dilated Cardiomyopathy (DCM)

Functional Magnetic Resonance Imaging in Infants

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation

Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids

A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)

Posterior Fossa Decompression With or Without Duraplasty for Chiari Type I Malformation With Syringomyelia

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

Tadalafil in Becker Muscular Dystrophy

Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy

Neurobiology and Treatment of Reading Disability in NF-1

A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus Retinitis